Table Info

Table 4.

Baseline clinical characteristics of PMBCL patients by treatment group

Characteristic	R-DA-EPOCH (n = 162)	RmNHL-BFM-90 (n = 69)	R-DA-EPOCH + nivolumab (n = 23)	P^※
Median age (range), years	32 (19–69)	29 (19–68)	31 (20–58)	0.111
≥ 45 years, n (%)	25 (15)	9 (13)	4 (17)	0.956
Male/female, n (%)	50/112 (31/69)	25/44 (36/64)	9/14 (39/61)	0.592
Ann Arbor stage
I–II, n (%)	132 (81)	64 (93)	17 (74)	0.041
III–IV, n (%)	30 (19)	5 (7)	6 (26)	0.041
ECOG-PS, n (%)
≥ 2	141 (87)	63 (91)	20 (87)	0.643
Bulky mass ≥ 6 cm, n (%)	151 (93)	67 (97)	22 (96)	0.479
Bulky mass ≥ 12 cm, n (%)	67 (41)	21 (30)	13 (57)	0.063
Involvement of pleura/pericardium, n (%)	116 (72)	48 (70)	18 (78)	0.725
Involvement of soft tissues/breast tissue, n (%)	38 (23)	15 (22)	6 (26)	0.907
Bone marrow involvement, n (%)	3 (2)	1 (1)	0	0.234
Elevated lactate dehydrogenase (N < 247 UI/L), n (%)	144 (89)	60 (87)	20 (87)	0.900
IPI score
0–1, n (%)	28 (17)	17 (25)	7 (30)	0.261
2, n (%)	98 (60)	41 (59)	9 (39)
3, n (%)	34 (21)	9 (13)	6 (26)
4–5, n (%)	2 (1)	2 (3)	1 (4)
Extramediastinal involvement, n (%)	30 (19)	5 (7)	6 (26)	0.041

This table summarizes the baseline clinical and demographic characteristics of PMBCL patients stratified by treatment protocol. ^※ The P-value of comparison between the treatment protocols. PMBCL: primary mediastinal large B-cell lymphoma; IPI: International Prognostic Index; R-DA-EPOCH: rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; RmNHL-BFM-90: rituximab, modified protocol NHL-BFM-90; ECOG: Eastern Cooperative Oncology Group; PS: performance status

Declarations

Author contributions

YKM: Conceptualization, Project administration, Data curation, Writing—review & editing. RRA: Investigation, Writing—original draft, Formal analysis, Visualization. NVR: Conceptualization, Investigation, Project administration, Data curation, Methodology, Resources, Writing—review & editing. BVB: Investigation, Data curation, Writing—review & editing. TVA: Investigation, Data curation, Writing—original draft. VLS: Methodology, Resources. IAS: Investigation, Data curation. TNO: Conceptualization, Writing—review & editing, Resources. RII: Investigation, Data curation, Writing—original draft. YAC: Methodology, Formal analysis, Visualization. AUM: Conceptualization. LEN: Investigation. SMK: Methodology, Formal analysis, Visualization. EEZ: Conceptualization. AMK: Conceptualization, Writing—review & editing, Resources. ABS: Conceptualization, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The present study has been accepted by the institutional ethical committee (National Medical Research Center for Hematology, Moscow, Russian Federation, protocol #165/30.06.2022). At this committee, we have approved the use of retrospective data from patients who received treatment before 2022 for our study. For patients who were included in the study and received treatment between 2007 and 2013, the study was conducted in accordance with the Helsinki Declaration of 1975, revised in 2008. As for the patients who received treatment after 2013, the study was conducted in accordance with the Helsinki Declaration of 1975, revised in 2013. All patients provided informed consent under National Medical Research Center for Hematology approved protocol allowing collection and analysis of data.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

This study was supported by RAKFOND (THE FOUNDATION FOR CANCER RESEARCH SUPPORT, Russia) grant [2.2020]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol. 2001;19:1855–64. [DOI] [PubMed]

Camus V, Drieux F, Jardin F. State of the art in the diagnosis, biology and treatment of primary mediastinal B-cell lymphoma: a review. Ann Lymphoma. 2022;6:13. [DOI]

Cazals-Hatem D, Lepage E, Brice P, Ferrant A, d’Agay MF, Baumelou E, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d’Etude des Lymphomes de l’Adulte”) study. Am J Surg Pathol. 1996;20:877–88. [DOI] [PubMed]

Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018;180:534–44. [DOI] [PubMed]

Cook MR, Williams LS, Dorris CS, Luo Y, Makambi K, Dunleavy K. Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients. Haematologica. 2024;109:846–56. [DOI] [PubMed] [PMC]

Vassilakopoulos T, Ferhanoglu B, Horowitz N, Mellios Z, Kaynar L, Zektser M, et al. RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIES. Hematol Oncol. 2021;39. [DOI]

Bakos J, Escribano Serrat S, Sawalha Y, Moskowitz A, Crawford A, Brooks TR, et al. Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Refractory or Relapsed after Frontline R-EPOCH Chemotherapy. Blood. 2023;142:3110. [DOI]

Dumke H, Phillips TJ, Kaminski MS, Carty S, Wilcox RA, Sano D, et al. Outcomes and prognostic factors of patients diagnosed with relapsed/refractory primary B-cell lymphoma: A retrospective study. J Clin Oncol. 2024;42:7081. [DOI]

Hang H, Zhou H, Ma L. Prognostic factors and clinical survival outcome in patients with primary mediastinal diffuse large B-cell lymphoma in rituximab era: A population-based study. Medicine (Baltimore). 2024;103:e37238. [DOI] [PubMed] [PMC]

10.

Shih HJ, Kuo MC, Lin TL, Kao HW, Wu JH, Hung YS, et al. Major impact of prognosis by age and sex in patients with primary mediastinal large B-cell lymphoma. Oncol Lett. 2024;27:57. [DOI] [PubMed] [PMC]

11.

Mangasarova YK, Abdurashidova RR, Magomedova AU, Margolin OV, Nesterova ES, Gorenkova LG, et al. Response-Adapted Strategy in the Treatment of Primary Mediastinal Large B-Cell Lymphoma: Results of a Prospective Single-Center Clinical Trial. Clin oncohematology. 2024;17:335–46. Russian. [DOI]

12.

Noerenberg D, Briest F, Hennch C, Yoshida K, Hablesreiter R, Takeuchi Y, et al. Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes. J Clin Oncol. 2024;42:452–66. [DOI] [PubMed]

13.

Pileri SA, Zinzani PL, Gaidano G, Falini B, Gaulard P, Zucca E, et al.; International Extranodal Lymphoma Study Group. Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma. 2003;44:S21–6. [DOI] [PubMed]

14.

Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142:141–5. [DOI] [PubMed] [PMC]

15.

Matsutani T, Akbay E, Elkord E. Editorial: Novel biomarkers in tumor immunity and immunotherapy. Front Immunol. 2024;15:1405082. [DOI] [PubMed] [PMC]

16.

Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood. 2018;132:2401–5. [DOI] [PubMed] [PMC]

17.

Chapuy B, Stewart C, Dunford AJ, Kim J, Wienand K, Kamburov A, et al. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood. 2019;134:2369–82. [DOI] [PubMed] [PMC]

18.

Tuveri S, Debackere K, Marcelis L, Dierckxsens N, Demeulemeester J, Dimitriadou E, et al. Primary mediastinal large B-cell lymphoma is characterized by large-scale copy-neutral loss of heterozygosity. Genes Chromosomes Cancer. 2022;61:603–15. [DOI] [PubMed]

19.

Kimm LR, deLeeuw RJ, Savage KJ, Rosenwald A, Campo E, Delabie J, et al. Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. Genes Chromosomes Cancer. 2007;46:1090–7. [DOI] [PubMed]

20.

Duns G, Viganò E, Ennishi D, Sarkozy C, Hung SS, Chavez E, et al. Characterization of DLBCL with a PMBL gene expression signature. Blood. 2021;138:136–48. [DOI] [PubMed]

21.

Shin G, Greer SU, Hopmans E, Grimes SM, Lee H, Zhao L, et al. Profiling diverse sequence tandem repeats in colorectal cancer reveals co-occurrence of microsatellite and chromosomal instability involving Chromosome 8. Genome Med. 2021;13:145. [DOI] [PubMed] [PMC]

22.

Sychevskaya KA, Kravchenko SK, Risinskaya NV, Misyurina AE, Nikulina EE, Babaeva FE, et al. Microsatellite instability (MSI, EMAST) in the pathogenesis of follicular lymphoma. Oncohematology. 2021;16:56–69. Russian. [DOI]

23.

Mangasarova YK, Magomedova AU, Nesterova ES, Volodicheva EM, Vorobyev VI, Kravchenko SK. Therapy for primary mediastinal large B-cell lymphoma in accordance with the R-DA-EPOCH-21 program: The first results. Ter Arkh. 2016;88:37–42. Russian. [DOI] [PubMed]

24.

Schoumans J, Suela J, Hastings R, Muehlematter D, Rack K, van den Berg E, et al. Guidelines for genomic array analysis in acquired haematological neoplastic disorders. Genes Chromosomes Cancer. 2016;55:480–91. [DOI] [PubMed]

25.

Ghaheri M, Kahrizi D, Yari K, Babaie A, Suthar RS, Kazemi E. A comparative evaluation of four DNA extraction protocols from whole blood sample. Cell Mol Biol (Noisy-le-grand). 2016;62:120–4. [DOI] [PubMed]

26.

ncbi.nlm.nih.gov/gene [Internet]. Bethesda: Courtesy of the National Library of Medicine; [cited 2024 Dec 25]. Available from: https://www.ncbi.nlm.nih.gov/gene/

27.

hgvs-nomenclature.org [Internet]. [cited 2024 Dec 25]. Available from: http://varnomen.hgvs.org/

28.

SIFT. Version 6.2.1 [Software]. [cited 2024 Dec 25]. Available from: https://sift.bii.a-star.edu.sg/

29.

PROVEAN. Version 1.1.5 [Software]. [cited 2024 Dec 25]. Available from: http://provean.jcvi.org/

30.

PolyPhen-2. Version 2.2.2 [Software]. [cited 2024 Dec 25]. Available from: http://genetics.bwh.harvard.edu/pph2/

31.

MutationTaster [Software]. [cited 2024 Dec 25]. Available from: https://www.mutationtaster.org/

32.

ClinVar [Internet]. Bethesda: Courtesy of the National Library of Medicine; [cited 2024 Dec 25]. Available from: https://www.ncbi.nlm.nih.gov/clinvar/

33.

Sidorova JV, Biderman BV, Nikulina EE, Sudarikov AB. A simple and efficient method for DNA extraction from skin and paraffin-embedded tissues applicable to T-cell clonality assays. Exp Dermatol. 2012;21:57–60. [DOI] [PubMed]

34.

Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20. [DOI] [PubMed] [PMC]

35.

Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589–95. [DOI] [PubMed] [PMC]

36.

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al.; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078–9. [DOI] [PubMed] [PMC]

37.

Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44:e108. [DOI] [PubMed] [PMC]

38.

Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164. [DOI] [PubMed] [PMC]

39.

RYR2:c.8162T>C [Internet]. [cited 2024 Nov 15]. Available from: https://franklin.genoox.com/variant/snp/chr1-237821276-T-C

40.

Seshat [Internet]. [cited 2024 Nov 15]. Available from: http://vps338341.ovh.net/

41.

Abdurashidova RR, Risinskaya NV, Mangasarova YK, Surin VL, Shupletsova IA, Chabaeva YA, et al. Analysis of microsatellite instability in primary mediastinal large B-cell lymphoma: Focus on PD-L1/PD-L2 and CIITA. Russ J Hematol Transfusiology. 2024;69:297–318. Russian. [DOI]

42.

Chambuso R, Kaambo E, Denny L, Gray CM, Williamson AL, Migdalska-Sęk M, et al. Investigation of Cervical Tumor Biopsies for Chromosomal Loss of Heterozygosity (LOH) and Microsatellite Instability (MSI) at the HLA II Locus in HIV-1/HPV Co-infected Women. Front Oncol. 2019;9:951. [DOI] [PubMed] [PMC]

43.

van Bussel MTJ, Beijnen JH, Brandsma D. Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. BMC Cancer. 2019;19:519. [DOI] [PubMed] [PMC]

44.

Camus V, Viailly PJ, Drieux F, Veresezan EL, Sesques P, Haioun C, et al. High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma. Blood Adv. 2023;7:7331–45. [DOI] [PubMed] [PMC]

45.

Firsova MV, Mendeleeva LP, Parovichnikova EN, Solovev MV, Kuzmina LA, Risinskaya NV, et al. Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma. Ter Arkh. 2021;93:778–84. Russian. [DOI] [PubMed]

46.

Risinskaya N, Kozhevnikova Y, Gavrilina O, Chabaeva J, Kotova E, Yushkova A, et al. Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL. Genes (Basel). 2022;13:398. [DOI] [PubMed] [PMC]

47.

Soloveva M, Solovev M, Risinskaya N, Nikulina E, Yakutik I, Biderman B, et al. Loss of Heterozygosity and Mutations in the RAS-ERK Pathway Genes in Tumor Cells of Various Loci in Multiple Myeloma. Int J Mol Sci. 2024;25:9426. [DOI] [PubMed] [PMC]

48.

Risinskaya N, Abdulpatakhov A, Chabaeva Y, Aleshina O, Gladysheva M, Nikulina E, et al. Biallelic Loss of 7q34 (TRB) and 9p21.3 (CDKN2A/2B) in Adult Ph-Negative Acute T-Lymphoblastic Leukemia. Int J Mol Sci. 2024;25:10482. [DOI] [PubMed] [PMC]

49.

Risinskaya N, Mangasarova Y, Nikulina E, Kozhevnikova Y, Chabaeva J, Yushkova A, et al. STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma. Curr Oncol. 2022;29:3449–59. [DOI] [PubMed] [PMC]